BR112018009646A2 - compostos de glicolipídeo e seus usos no tratamento de tumores - Google Patents

compostos de glicolipídeo e seus usos no tratamento de tumores

Info

Publication number
BR112018009646A2
BR112018009646A2 BR112018009646A BR112018009646A BR112018009646A2 BR 112018009646 A2 BR112018009646 A2 BR 112018009646A2 BR 112018009646 A BR112018009646 A BR 112018009646A BR 112018009646 A BR112018009646 A BR 112018009646A BR 112018009646 A2 BR112018009646 A2 BR 112018009646A2
Authority
BR
Brazil
Prior art keywords
tumors
treatment
glycolipids
glycolipid compounds
compounds
Prior art date
Application number
BR112018009646A
Other languages
English (en)
Other versions
BR112018009646B1 (pt
Inventor
Borisovich Tuzikov Alexander
Yurievna Korchagina Elena
Griffiths Graham
Vladimirovich Bovin Nicolai
Henry Stephen
Shaw Stephen
Original Assignee
Agalimmune Ltd
Kode Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agalimmune Ltd, Kode Biotech Ltd filed Critical Agalimmune Ltd
Publication of BR112018009646A2 publication Critical patent/BR112018009646A2/pt
Publication of BR112018009646B1 publication Critical patent/BR112018009646B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

a invenção se refere aos novos compostos de glicolipídeo e composições farmacêuticas compreendendo os ditos glicolipídeos e aos processos para preparar os ditos glicolipídeos. a invenção também se refere aos ditos glicolipídeos para o uso no tratamento de tumores e aos métodos para tratar tumores usando os ditos glicolipídeos.
BR112018009646-6A 2015-11-11 2015-11-11 Compostos de glicolipídeo, sua composição farmacêutica e seu uso no tratamento de tumores BR112018009646B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2015/000766 WO2017082753A1 (en) 2015-11-11 2015-11-11 Glycolipid compounds and their uses in the treatment of tumours

Publications (2)

Publication Number Publication Date
BR112018009646A2 true BR112018009646A2 (pt) 2018-12-11
BR112018009646B1 BR112018009646B1 (pt) 2020-03-31

Family

ID=56117941

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018009646-6A BR112018009646B1 (pt) 2015-11-11 2015-11-11 Compostos de glicolipídeo, sua composição farmacêutica e seu uso no tratamento de tumores

Country Status (13)

Country Link
US (1) US20180344805A1 (pt)
EP (1) EP3374367A1 (pt)
JP (1) JP6758375B2 (pt)
KR (1) KR102517641B1 (pt)
CN (1) CN108463466B (pt)
AU (1) AU2015414272B2 (pt)
BR (1) BR112018009646B1 (pt)
CA (1) CA3004107C (pt)
HK (1) HK1258843A1 (pt)
IL (1) IL259205B (pt)
MX (1) MX2018005828A (pt)
RU (1) RU2719486C2 (pt)
WO (1) WO2017082753A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023202155B1 (en) * 2022-04-08 2023-10-26 Kode Biotech Limited Large scale production of n-acetyllactosamine derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820628B2 (en) 2005-02-22 2010-10-26 University Of Massachusetts Medical School Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding
DK2201025T3 (en) * 2007-10-12 2016-06-27 Kode Biotech Ltd functional lipidkonstruktionsprodukter
MX360254B (es) 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
NZ732618A (en) * 2014-11-21 2020-10-30 Stephen Micheal Henry Multivalent ligand-lipid constructs

Also Published As

Publication number Publication date
RU2018121273A3 (pt) 2019-12-13
AU2015414272A1 (en) 2018-04-26
WO2017082753A1 (en) 2017-05-18
MX2018005828A (es) 2019-02-20
IL259205A (en) 2018-07-31
KR102517641B1 (ko) 2023-04-05
AU2015414272B2 (en) 2021-04-22
JP2018533616A (ja) 2018-11-15
HK1258843A1 (zh) 2019-11-22
RU2018121273A (ru) 2019-12-13
CN108463466A (zh) 2018-08-28
CA3004107C (en) 2023-10-17
CN108463466B (zh) 2021-07-09
KR20180099651A (ko) 2018-09-05
EP3374367A1 (en) 2018-09-19
US20180344805A1 (en) 2018-12-06
RU2719486C2 (ru) 2020-04-17
JP6758375B2 (ja) 2020-09-23
IL259205B (en) 2021-06-30
BR112018009646B1 (pt) 2020-03-31
CA3004107A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112017027414A2 (pt) Derivados hidroxiéster, processo para prepará- los e composições farmacêuticas os contendo
BR112018074972A2 (pt) derivados de adenosina para uso no tratamento de câncer
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
MA43807A (fr) Préparation et composition de traitement de tumeurs malignes
BR112017008840A2 (pt) intensificador de inibidores do homólogo 2 de zeste
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
BR112018070357A2 (pt) anticorpos anticomplemento contra o fator bb e seus usos
BR112017025781A2 (pt) derivados de 2-(pirazolopiridin-3-il)pirimidina como inibidores de jak
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
CL2015002897A1 (es) Inhibidores de bace1
BR112017003705A2 (pt) compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea
BR112016016870A8 (pt) derivados de icariina, seus usos, e composição farmacêutica
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CR20170264A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
BR112017022022A8 (pt) Arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)
CR20160133A (es) Derivados de fenilalanina sustituidos
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
BR112018009745A8 (pt) compostos heterocíclicos para o tratamento de doença
BR112017028616A2 (pt) acentuador de inibidores de homólogo de zeste 2

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/11/2015, OBSERVADAS AS CONDICOES LEGAIS.